Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma

American Journal of Hematology

Volumn 84, Issue 6, 2009, Pages 335-337

  Hosing, Chitra ^a   Saliba, Rima M ^a   Ahlawat, Sheena ^a   Körbling, Martin ^a   Kebriaei, Partow ^a   Alousi, Amin ^a   De Lima, Marcos ^a   Okoroji, Julia Grace ^a   McMannis, John ^a   Qazilbash, Muzaffar ^a   Anderlini, Paolo ^a   Giralt, Sergio ^a   Champlin, Richard E ^a   Khouri, Issa ^a   Popat, Uday ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHYLPREDNISOLONE; NAVELBINE; RITUXIMAB; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RELAPSE; CONSULTATION; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PATIENT REFERRAL; PRIORITY JOURNAL; RECURRENT CANCER; SEX DIFFERENCE; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 66849102131     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21400     Document Type: Article

References (25)

1. Strehl J, Mey U, Glasmacher A, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non- Hodgkin's lymphoma: a meta-analysis. Haematologica 2003;88:1304-1315. (Pubitemid 37456386)
2. Philip T, Chauvin F, Bron D, et al. PARMA international protocol: Pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol 1991;2 (Suppl 1):57-64.
3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
4. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis. Blood 2000;96:2399-2404.
5. Popat U, Hosing C, Saliba RM, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:1015-1023 (Pubitemid 38744788)
6. Anderlini P. Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): Current status. Cytotherapy 2002;4:241-251. (Pubitemid 34905055)
7. Korbling M, Haas R, Knauf W, et al. Therapeutic efficacy of autologous blood stem cell transplantation (ABSCT): The role of cytotoxic/cytokine stem cell mobilization. Bone Marrow Transplant 1990;5 (Suppl 1):39-40. (Pubitemid 20118154)
8. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353-357. (Pubitemid 26046102)
9. Donato ML, Champlin RE, Van Besien KW, et al. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non- Hodgkin's lymphoma. Leuk Lymphoma 1999;35:317-324.
10. Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005;23:2240-2247. (Pubitemid 46218716)
11. Ameen RM, Alshemmari SH, Alqallaf D. Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies. Clin Lymphoma Myeloma 2008;8:106-110.
12. Koenigsmann M, Jentsch-Ullrich K, Mohren M, et al. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004;44:777-784. (Pubitemid 38608258)
13. Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998;4:311-316. (Pubitemid 28122743)
14. Ketterer N, Salles G, Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998;103:235-242. (Pubitemid 28470825)
15. Morton J, Morton A, Bird R, et al. Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leuk Res 1997;21:21-27. (Pubitemid 27073238)
16. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-2555.
17. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-3794. (Pubitemid 24175570)
18. Nademanee A, Sniecinski I, Schmidt GM, et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994;12:2176-2186. (Pubitemid 24983476)
19. Kuittinen T, Nousiainen T, Halonen P, et al. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:907-912. (Pubitemid 38660123)
20. Akhtar S, Weshi AE, Rahal M, et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: A single institution result of 168 patients. Leuk Lymphoma 2008;49:769-778.
21. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-1056.
22. Tarella C, Di Nicola M, Caracciolo D, et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002;30:725-732. (Pubitemid 36007752)
23. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37:719-724.
24. Perry AR, Watts MJ, Peniket AJ, et al. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant 1998;21:1201-1205. (Pubitemid 28318746)
25. Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003;44:815-820. (Pubitemid 36410987)